Mutant IDH1 blocks neutropoiesis by repressing myeloid progenitor programs.

Area of Science:

• Hematology
• Cancer Biology
• Epigenetics

Background:

• Isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations are common in acute leukemias.
• The precise mechanisms by which these mutations drive cancer are not fully understood.

Purpose of the Study:

• To investigate the distinct roles of IDH1 and IDH2 mutations in driving hematopoietic neoplasms.
• To analyze the epigenetic and transcriptional consequences of IDH1 mutations in myeloid progenitors.

Main Methods:

• DNA methylation and transcriptional analysis of IDH1/IDH2-mutant acute myeloid leukemia (AML) samples.
• Utilized a genetically engineered inducible mouse model for studying heterozygous Idh1 mutations in a pre-leukemic setting.

Main Results:

• IDH1 mutations induce neutrophil lineage-specific epigenetic alterations and impaired neutrophil differentiation.
• A cell-intrinsic block in neutrophil differentiation was observed, caused by repression of key myeloid transcription programs, including Cebpe.
• The differentiation block was reversible upon restoration of Cebpe expression or treatment with hypomethylating agents.

Conclusions:

• IDH1 mutations cause a reversible, pre-leukemic impairment of neutrophil differentiation in hematopoiesis.
• This impairment correlates with elevated IDH1 expression in myeloid progenitors and may explain the association of IDH1 mutations with myeloid neoplasms.